Docket No.: 5999-0526PUS3

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Louise EDWARDS et al.

Application No.: 10/588,751

Confirmation No.: 4520

Filed: March 13, 2007

Art Unit: 1614

For: TRIAZOLE COMPOUNDS AND THEIR USE

AS METABOTROPIC GLUTAMATE

RECEPTOR ANTAGONISTS

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

a. Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.

b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned. C. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120: U.S. Appl. No(s) and U.S. Filing Date PCT/US2005/005200 filed February 17, 2005 III. **CONCISE EXPLANATION OF THE RELEVANCE** (check at least one box) DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy. b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows: c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3). \boxtimes d. OTHER - The following additional information is provided for the Examiner's consideration. Corresponding to the Information Disclosure Statement filed on June 13, 2007, enclosed is reference IN-183333 cited in the Form SB08 for consideration.

Application No.: 10/588,751

Docket No.: 5999-0526PUS3

IV. <u>FEES</u> (check one box) This Information Disclosure Statement is being filed concurrently with the filing a. of a new patent application; therefore, no fee is required. Ъ. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required. This Information Disclosure Statement is being filed within three months of the c. filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's.) d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required. \boxtimes f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p). g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)). No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached. or

3

Docket No.: 5999-0526PUS3

ADM/mao

Application No.: 10/588,751

Docket No.: 5999-0526PUS3 Application No.: 10/588,751 See the statement below. No fee is required. V. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box) The undersigned hereby states that: Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)

Application No.: 10/588,751	Docket No.: 5999-0526PUS3
The required fee is listed of	on the attached Fee Transmittal.
No fee is required.	
undersigned. If it is determined that this	s concerning this IDS, he/she is requested to contact the IDS has been filed under the wrong rule, the PTO is proper rule and charge the appropriate fee to Deposit
replies, to charge payment or credit any	is hereby authorized in this, concurrent, and future overpayment to our Deposit Account No. 02-2448 for F.R. § 1.16 or under § 1.17; particularly, extension of
Dated: June 27, 2007	Respectfully submitted, By
Attachment(s): PTO/SB/08 Document(s) Foreign Search Report(s) Fee Other:	Attorney for Applicant

Complete if Known Substitute for form 1449/PTO Application Number 10/588,751-Conf. #4520 INFORMATION DISCLOSURE Filing Date March 13, 2007 STATEMENT BY APPLICANT First Named Inventor Louise EDWARDS Art Unit 1614 (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet of Attorney Docket Number 5999-0526PUS3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁸ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
						Г

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.ussto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
xaminer nitials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7	
	CA	CAPLUS Copyright 2004 ACS on STN, 2004:742244 CAPLUS< <loginid::20041122>> DN 141:207210, An improved process for the preparation of 3-phenoxy-methyl-4-phenyl-1,2,4-triazol-5-one derivatives via thionation with P2S5 and cyclocondensation, IN 183333.</loginid::20041122>		
		triazol-5-one derivatives via thionation with P2S5 and cyclocondensation, IN 183333.		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Examiner	Date	
Signature	Considered	
	······································	

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.